Ledyard, CT, United States of America

HuaZhu Ke

This inventor holds 6 USPTO granted patents. Top assignee: Pfizer Corporation. Active years: 2000-2006.


% Patents Active = 66.7

Average Co-Inventor Count = 2.6

ph-index = 3

Forward Citations = 78(Granted Patents)


Company Filing History:


Years Active: 2000-2006

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations of HuaZhu Ke in Pharmaceutical Science

Introduction

HuaZhu Ke is a notable inventor based in Ledyard, CT (US), recognized for his contributions to pharmaceutical science. He holds a total of 6 patents, showcasing his innovative approach to developing new pharmaceutical compositions and methods.

Latest Patents

Among his latest patents, HuaZhu Ke has developed pharmaceutical compositions, kits, and methods that comprise combinations of estrogen agonists/antagonists, estrogens, and progestins. One significant invention relates to the use of (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or its nontoxic pharmacologically acceptable acid addition salts in combination with estrogens. Another important patent focuses on EP4 receptor selective agonists for the treatment of osteoporosis, further emphasizing his commitment to advancing medical treatments.

Career Highlights

HuaZhu Ke is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to contribute significantly to the field of pharmaceuticals, particularly in the development of innovative treatments.

Collaborations

HuaZhu Ke collaborates with esteemed colleagues such as David D. Thompson and Kimberly O. Cameron, enhancing the research and development efforts within his team.

Conclusion

HuaZhu Ke's innovative work in pharmaceutical compositions and methods has made a significant impact in the field. His patents reflect a dedication to improving health outcomes through scientific advancements.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…